Circulating tumor cells in early breast cancer: A connection with vascular invasion

Maltoni, Roberta; Fici, Pietro; Amadori, Dino; Gallerani, Giulia; Cocchi, Claudia; Zoli, Martina; Rocca, Andrea; Cecconetto, Lorenzo; Folli, Secondo; Scarpi, Emanuela; Serra, Patrizia; Fabbri, Francesco

doi:10.1016/j.canlet.2015.06.020

Cited by 35 publications

(21 citation statements)

References 36 publications

(49 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, it is of clinical significance to detect CTCs in the peripheral circulation of patients with malignant tumors. The relationship between the prognosis of patients with breast cancer and CTCs has been demonstrated in many previous studies [ 17 – 19 ]. Compared with histological examination of tumor tissue, CTCs are easy to obtain, can be treated repeatedly, and are relatively noninvasive.…”

Section: Discussionmentioning

confidence: 88%

Detection of Circulating Tumor Cells by Fluorescent Immunohistochemistry in Patients with Esophageal Squamous Cell Carcinoma: Potential Clinical Applications

Guan

Zhao

et al. 2016

Med Sci Monit

View full text Add to dashboard Cite

BackgroundCirculating tumor cells (CTCs) are tumor cells that leave the primary tumor site and enter the bloodstream, where they can spread to other organs; they are very important in the diagnosis, treatment, and prognosis of malignant tumors. However, few studies have investigated CTCs in esophageal squamous cell carcinoma (ESCC). The aim of this study was to investigate the CTCs in blood of ESCC patients and its potential relevance to clinicopathological features and prognosis.Material/MethodsCTCs were acquired by a negative enrichment method that used magnetic activated cell sorting (MACSTM). Fluorescent immunohistochemistry (IHC) was used to identify the CTCs. Then, the positive CTC patients with ESCC were analyzed, after which the relationship between CTCs and clinicopathologic features was evaluated.ResultsIn the present study, 62 out of 140 (44.3%) patients with ESCC were positive for CTCs. The positive rate of CTCs was significantly related with stage of ESCC patients (P=0.013). However, there was no relationship between CTC status and age, sex, smoking tumor history, tumor location, differentiation of tumor, lymphatic invasion, or lymph venous invasion (P>0.05). Kaplan-Meier analysis showed that patients positive for CTCs had significantly shorter survival time than patients negative for CTCs. Multivariate analysis demonstrated that stage and CTC status were significant prognostic factors for patients with ESCC.ConclusionsCTCs positivity is an independent prognostic biomarker that indicates a worse prognosis for patients with ESCC.

show abstract

Section: Discussionmentioning

confidence: 88%

Detection of Circulating Tumor Cells by Fluorescent Immunohistochemistry in Patients with Esophageal Squamous Cell Carcinoma: Potential Clinical Applications

Guan

Zhao

et al. 2016

Med Sci Monit

View full text Add to dashboard Cite

show abstract

“…Finally, 50 studies were eligible for meta-analysis (Fig. 1)4591112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657.…”

Section: Resultsmentioning

confidence: 99%

Circulating tumor cell status monitors the treatment responses in breast cancer patients: a meta-analysis

Yan

Cui

Chen

et al. 2017

Sci Rep

View full text Add to dashboard Cite

Whether circulating tumor cells (CTCs) can be used as an indicator of treatment response in breast cancer (BC) needs to be clarified. We addressed this issue by a meta-analysis. PubMed, EMBase and Cochrane library databases were searched in June 2016. Effect measures were estimated as pooled risk ratio (RR), odds ratio (OR) or mean difference by fixed- or random-effect models, according to heterogeneity of included studies. In total, 50 studies with 6712 patients were recruited. Overall analysis showed that there was a significant reduction of CTC-positive rate (RR = 0.68, 95% CI: 0.61–0.76, P < 0.00001) after treatment. Subgroup analyses revealed that neoadjuvant treatment, adjuvant treatment, metastatic treatment or combination therapy could reduce the CTC-positive rate, but surgery could not; moreover, the reduction was only found in HER2+ or HER2- patients but not in the triple-negative ones. Reduction of CTC-positive rate was associated with lower probability of disease progression (OR = 0.54, 95% CI: 0.33–0.89, P = 0.01) and longer overall survival period (mean difference = 11.61 months, 95% CI: 8.63–14.59, P < 0.00001) as well as longer progression-free survival period (mean difference = 5.07 months, 95% CI: 2.70–7.44, P < 0.0001). These results demonstrate that CTC status can serve as an indicator to monitor the effectiveness of treatments and guide subsequent therapies in BC.

show abstract

“…Immunocytological, molecular, densitometric and/or size-dependent CTC enrichment methods could lead to significantly different results from those obtained by EpCAM-based technologies [58,59,60,61,62,63]. Approaches that combine physical and cellular properties of CTCs have produced interesting results [64,65,66], as previously reported by our group [67,68]. Our approach, albeit improvable, was based on densitometric enrichment followed by an immunocytological detection step and allowed us to detect three CTC classes: EpCAM + /CKs + , EpCAM − /CKs + and EpCAM + /CKs − cells.…”

Section: Circulating Tumor Cells (Ctcs) and Eacmentioning

confidence: 77%

Circulating Tumor Cells in the Adenocarcinoma of the Esophagus

Gallerani

Fabbri

2016

IJMS

Self Cite

View full text Add to dashboard Cite

Circulating tumor cells (CTCs) are elements of indisputable significance as they seem to be responsible for the onset of metastasis. Despite this, research into CTCs and their clinical application have been hindered by their rarity and heterogeneity at the molecular and cellular level, and also by a lack of technical standardization. Esophageal adenocarcinoma (EAC) is a highly aggressive cancer that is often diagnosed at an advanced stage. Its incidence has increased so much in recent years that new diagnostic, prognostic and predictive biomarkers are urgently needed. Preliminary findings suggest that CTCs could represent an effective, non-invasive, real-time assessable biomarker in all stages of EAC. This review provides an overview of EAC and CTC characteristics and reports the main research results obtained on CTCs in this setting. The need to carry out further basic and translational research in this area to confirm the clinical usefulness of CTCs and to provide oncologists with a tool to improve therapeutic strategies for EAC patients was herein highlighted.

show abstract

Circulating tumor cells in early breast cancer: A connection with vascular invasion

Cited by 35 publications

References 36 publications

Detection of Circulating Tumor Cells by Fluorescent Immunohistochemistry in Patients with Esophageal Squamous Cell Carcinoma: Potential Clinical Applications

Detection of Circulating Tumor Cells by Fluorescent Immunohistochemistry in Patients with Esophageal Squamous Cell Carcinoma: Potential Clinical Applications

Circulating tumor cell status monitors the treatment responses in breast cancer patients: a meta-analysis

Circulating Tumor Cells in the Adenocarcinoma of the Esophagus

Contact Info

Product

Resources

About